Transarterial chemoembolization: Clinical Trials

16 trials of Transarterial chemoembolization, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 5 unknown, 2 recruiting, 2 withdrawn. 16 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 316Completed 5, Unknown 5, Recruiting 2, Withdrawn 2, Active not recruiting 1, Terminated 1
Phase 21Completed 1

Follow Transarterial chemoembolization: new trials by email Literature Review of Transarterial chemoembolization trials Research Report on Transarterial chemoembolization

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NRT6003 Injection, cTACE - Unresectable Hepatocellular Carcinoma
Phase 3Active not recruitingChengdu New Radiomedicine Technology Co. LTD.1082025-04-152026-06-09
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Atezolizumab, Bevacizumab, TACE - Hepatocellular Carcinoma
Phase 3RecruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest4342021-07-062025-01-07
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
Sorafenib, Transarterial chemoembolization - Hepatocellular Carcinoma
Phase 3UnknownSun Yat-sen University1582019-09-152020-03-25
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Stereotactic Body Radiation, Transarterial Chemoembolization - Hepatocellular Carcinoma
Phase 3RecruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1282019-05-272025-03-11
Adjuvant Radiotherapy Comparing TACE for Curative HCC
Transarterial chemoembolization, Radiotherapy - Hepatocellular Carcinoma
Phase 3UnknownGuangxi Medical University1502019-05-012023-01-27
Adjuvant Therapies for Patients With HCC and MVI
TACE, Sorafenib, TACE plus sorafenib - Hepatocellular Carcinoma
Phase 3UnknownGuangxi Medical University2402019-02-012020-01-10
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Lenvatinib, PD-1 antibody, TACE - Hepatocellular Carcinoma
Phase 3WithdrawnSun Yat-sen University2019-01-012019-05-02
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, Folfox Protocol - HepatoCellular Carcinoma
Phase 3CompletedSun Yat-sen University3152016-10-012023-06-12
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen - Hepatocellular Carcinoma
Phase 3CompletedSun Yat-sen University2142016-08-012024-07-23
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent - Child-Pugh Class A, Child-Pugh Class B
Phase 3TerminatedStanford University132016-02-272024-03-12
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Transarterial chemoembolization (TACE), Radiofrequency ablation combined with TACE, Microwave ablation combined with TACE - Liver Cancer
Phase 3UnknownSherief Abd-Elsalam502015-01-012018-01-09
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
liver resection, transarterial chemoembolization, carboplatin - Hepatocellular Carcinoma
Phase 3UnknownSun Yat-sen University1982014-03-012016-04-28
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
Transarterial Chemoembolization, CyberKnife SBRT - Recurrent Hepatocellular Carcinoma
Phase 3WithdrawnAccuray Incorporated2011-02-012012-02-20
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
sunitinib malate, Placebo, transarterial chemoembolization - Liver Cancer
Phase 2 / Phase 3CompletedFederation Francophone de Cancerologie Digestive782010-07-012022-03-18
Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
transarterial chemoembolization - Liver Cancer
Phase 3CompletedGuangdong Provincial People's Hospital1622008-01-012014-01-17
Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs
Transarterial chemoembolization, Percutaneous ethanol injection therapy - Hepatocellular Carcinoma
Phase 3CompletedSeoul National University Hospital222005-10-012013-12-04

Conditions studied

Carcinoma, Hepatocellular (14)  ·  Liver Neoplasms (4)

Sponsors

Sun Yat-sen University (5)  ·  Guangxi Medical University (2)  ·  Accuray Incorporated (1)  ·  Chengdu New Radiomedicine Technology Co. LTD. (1)  ·  Federation Francophone de Cancerologie Digestive (1)  ·  Guangdong Provincial People's Hospital (1)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)  ·  Seoul National University Hospital (1)  ·  Sherief Abd-Elsalam (1)  ·  Stanford University (1)

Countries

China (9)  ·  France (2)  ·  Japan (2)  ·  United States (2)  ·  Austria (1)  ·  Canada (1)  ·  Egypt (1)  ·  Germany (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Ming Shi, MD (3)  ·  Daniel Chang, MD (2)  ·  Albert Koong, MD, PhD (1)  ·  Elshazly Sheta, Professor (1)  ·  Erqi Liu Pollom, MD (1)  ·  Ferial El-kalla, Professor (1)  ·  Gaojun Teng (1)  ·  Ibrahim Amer, Consultant (1)  ·  J H Yoon, Professor (1)  ·  Jordi Bruix, Prof. Dr. (1)  ·  Michael Lock, M.D. (1)  ·  Mohamed Elgharib, Professor (1)  ·  Mohamed Elhendawy, Consultant (1)  ·  Mohamed Hebbar, MD (1)

Results publications

PMID 32576496, PMID 34648352, PMID 38568599, PMID 40302359

NIH funding

P30CA124435 (1)